Evidence map›Paper›PMID 29783999›Full record

ArticleJournal of translational medicine2018

Identification of micro-RNA expression profile related to recurrence in women with ESMO low-risk endometrial cancer.

Tiphaine de Foucher, Maria Sbeih, Jenifer Uzan, Sofiane Bendifallah, Marine Lefevre, Nathalie Chabbert-Buffet, Selim Aractingi, Catherine Uzan, Issam Abd Alsalam, Rana Mitri and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tiphaine de FoucherINSERM, UMR S 938, Sorbonne University, Paris, France.ORCID 0000-0003-0275-2452
Maria SbeihINSERM, UMR S 938, Sorbonne University, Paris, France.
Jenifer UzanDepartment of Obstetrics and Gynaecology, Creteil Intercommunal Hospital, Université Paris Est, Paris XII, Créteil, France.
Sofiane BendifallahDepartment of Obstetrics and Gynaecology, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris, Sorbonne University, Paris, France.
Marine LefevreDepartment of Pathology, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris, Sorbonne University, Paris, France.
Nathalie Chabbert-BuffetINSERM, UMR S 938, Sorbonne University, Paris, France.
Selim AractingiINSERM, UMR S 938, Sorbonne University, Paris, France.
Catherine UzanDepartment of Surgery and Oncological Gynaecology, Pitié-Salpétrière University Hospital, Assistance Publique des Hôpitaux de Paris, Sorbonne University, Paris, France.
Issam Abd AlsalamDepartment of Pathology, Creteil Intercommunal Hospital, Université Paris Est, Paris XII, Créteil, France.
Rana MitriDepartment of Pathology, Creteil Intercommunal Hospital, Université Paris Est, Paris XII, Créteil, France.
Romain H FontaineINSERM, UMR S 938, Sorbonne University, Paris, France.
Emile DaraïINSERM, UMR S 938, Sorbonne University, Paris, France.
Bassam HaddadDepartment of Obstetrics and Gynaecology, Creteil Intercommunal Hospital, Université Paris Est, Paris XII, Créteil, France.
Céline MéhatsCochin Institute, Inserm U1016, CNRS 8104, University René Descartes, Paris, France.
Marcos BallesterINSERM, UMR S 938, Sorbonne University, Paris, France.
Geoffroy CanlorbeINSERM, UMR S 938, Sorbonne University, Paris, France. geoffroy.canlorbe@aphp.fr.
Cyril TouboulDepartment of Obstetrics and Gynaecology, Creteil Intercommunal Hospital, Université Paris Est, Paris XII, Créteil, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundActual European pathological classification of early-stage endometrial cancer (EC) may show insufficient accuracy to precisely stratify recurrence risk, leading to potential over or under treatment. Micro-RNAs are post-transcriptional regulators involved in carcinogenic mechanisms, with some micro-RNA patterns of expression associated with EC characteristics and prognosis. We previously demonstrated that downregulation of micro-RNA-184 was associated with lymph node involvement in low-risk EC (LREC). The aim of this study was to evaluate whether micro-RNA signature in tumor tissues from LREC women can be correlated with the occurrence of recurrences.

methodsMicroRNA expression was assessed by chip analysis and qRT-PCR in 7 formalin-fixed paraffin-embedded (FFPE) LREC primary tumors from women whose follow up showed recurrences (R+) and in 14 FFPE LREC primary tumors from women whose follow up did not show any recurrence (R-), matched for grade and age. Various statistical analyses, including enrichment analysis and a minimum p-value approach, were performed.

resultsThe expression levels of micro-RNAs-184, -497-5p, and -196b-3p were significantly lower in R+ compared to R- women. Women with a micro-RNA-184 fold change < 0.083 were more likely to show recurrence (n = 6; 66%) compared to those with a micro-RNA-184 fold change > 0.083 (n = 1; 8%), p = 0.016. Women with a micro-RNA-196 fold change < 0.56 were more likely to show recurrence (n = 5; 100%) compared to those with a micro-RNA-196 fold change > 0.56 (n = 2; 13%), p = 0.001.

conclusionsThese findings confirm the great interest of micro-RNA-184 as a prognostic tool to improve the management of LREC women.

Indexed as

Gene Expression ProfilingAgedAged, 80 and overDown-RegulationEndometrial NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansMicroRNAsMiddle AgedNeoplasm Recurrence, LocalRisk FactorsUp-RegulationMicroRNAsLow risk endometrial cancerMicroRNA-184MicroRNAsRecurrence

Identifiers

PMID29783999
PMCPMC5963057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.